5G1: ALXN filed an IND to begin a Phase I trial.

Alexion Pharmaceuticals Inc. (ALXN), New Haven, Conn. Product: 5G1.1-SC complement inhibitor Indication: Inflammation during cardiopulmonary bypass Status: ALXN filed an IND to begin a Phase I trial. ...